Log in

NASDAQ:CHRS - Coherus Biosciences Stock Price, Forecast & News

$16.26
-0.53 (-3.16 %)
(As of 03/29/2020 02:14 AM ET)
Today's Range
$15.69
Now: $16.26
$17.00
50-Day Range
$11.67
MA: $18.72
$22.53
52-Week Range
$10.86
Now: $16.26
$23.91
Volume769,915 shs
Average Volume1.60 million shs
Market Capitalization$1.15 billion
P/E Ratio13.66
Dividend YieldN/A
Beta2.58
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Read More
Coherus Biosciences logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHRS
CUSIPN/A
Phone650-649-3530

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$356.07 million
Cash Flow$1.29 per share
Book Value$1.50 per share

Profitability

Net Income$89.83 million

Miscellaneous

Employees232
Market Cap$1.15 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.


Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions

How has Coherus Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Coherus Biosciences' stock was trading at $15.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CHRS stock has increased by 2.5% and is now trading at $16.26. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Coherus Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Coherus Biosciences.

When is Coherus Biosciences' next earnings date?

Coherus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Coherus Biosciences.

How were Coherus Biosciences' earnings last quarter?

Coherus Biosciences Inc (NASDAQ:CHRS) issued its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported $0.56 earnings per share for the quarter, missing analysts' consensus estimates of $0.68 by $0.12. The biotechnology company earned $123.86 million during the quarter, compared to analysts' expectations of $123.60 million. Coherus Biosciences had a net margin of 25.23% and a return on equity of 302.63%. View Coherus Biosciences' earnings history.

What price target have analysts set for CHRS?

7 brokerages have issued twelve-month price objectives for Coherus Biosciences' stock. Their forecasts range from $27.00 to $43.00. On average, they expect Coherus Biosciences' stock price to reach $32.86 in the next twelve months. This suggests a possible upside of 102.1% from the stock's current price. View analysts' price targets for Coherus Biosciences.

Has Coherus Biosciences been receiving favorable news coverage?

News stories about CHRS stock have trended very negative recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Coherus Biosciences earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutCoherus Biosciences.

Who are some of Coherus Biosciences' key competitors?

What other stocks do shareholders of Coherus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Chembio Diagnostics (CEMI), Halozyme Therapeutics (HALO), Intelsat (I), Exelixis (EXEL), Bank of America (BAC), Heron Therapeutics (HRTX), Immunomedics (IMMU), Fossil Group (FOSL), Progenics Pharmaceuticals (PGNX) and Sangamo Therapeutics (SGMO).

Who are Coherus Biosciences' key executives?

Coherus Biosciences' management team includes the following people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)
  • Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)
  • Dr. Peter K. Watler, Chief Technical Officer (Age 57)
  • Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)
  • Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64)

What is Coherus Biosciences' stock symbol?

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus Biosciences' major shareholders?

Coherus Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Temasek Holdings Private Ltd (10.53%), State Street Corp (4.97%), Lord Abbett & CO. LLC (4.38%), Alliancebernstein L.P. (3.11%), Nuveen Asset Management LLC (2.75%) and UBS Asset Management Americas Inc. (2.73%). Company insiders that own Coherus Biosciences stock include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View institutional ownership trends for Coherus Biosciences.

Which institutional investors are selling Coherus Biosciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Partner Fund Management L.P., First Trust Advisors LP, Chartwell Investment Partners LLC, Credit Suisse AG, 361 Capital LLC, PNC Financial Services Group Inc., and Russell Investments Group Ltd.. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, James Healy, Jean-Frederic Viret, and Vincent R Anicetti. View insider buying and selling activity for Coherus Biosciences.

Which institutional investors are buying Coherus Biosciences stock?

CHRS stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Temasek Holdings Private Ltd, State Street Corp, Hawk Ridge Capital Management LP, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., Charles Schwab Investment Management Inc., and Panagora Asset Management Inc.. View insider buying and selling activity for Coherus Biosciences.

How do I buy shares of Coherus Biosciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Coherus Biosciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $16.26.

How big of a company is Coherus Biosciences?

Coherus Biosciences has a market capitalization of $1.15 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe. View additional information about Coherus Biosciences.

What is Coherus Biosciences' official website?

The official website for Coherus Biosciences is http://www.coherus.com/.

How can I contact Coherus Biosciences?

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]


MarketBeat Community Rating for Coherus Biosciences (NASDAQ CHRS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  378 (Vote Outperform)
Underperform Votes:  362 (Vote Underperform)
Total Votes:  740
MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel